MLTX,MoonLake Immunotherapeutics | Healthcare

Healthcare

MLTX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

MoonLake ImmunotherapeuticsMLTX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases.

The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis.

MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Latest News >

Science Applications International Fiscal Q1 Adjusted Earnings, Revenue Decline; Fiscal 2025 Guidance Reiterated

Jun 3, 2024

07:40 AM EDT, 06/03/2024 (MT Newswires) -- Science Applications International ( SAIC ) reported fiscal Q1 adjusted earnings Monday of $1.92 per diluted share, down from $2.14 a year earlier. Analysts polled by Capital IQ expected $1.92. Revenue for the fiscal quarter ended May 3 was $1.85 billion, down from $2.03 billion a year earlier. Analysts surveyed by Capital IQ...

Update: Generation Mining Applauds International Energy Forum Report Outlining EV Copper Hurdles

Jun 3, 2024

07:37 AM EDT, 06/03/2024 (MT Newswires) -- Generation Mining ( GENMF ) on Monday cheered a recent report by the International Energy Forum outlining rising global demand for copper amid the energy transition. The report, titled Copper Mining and Vehicle Electrification, found that the world will not be able to produce enough copper to transition to 100% electric vehicle production...

Structure Therapeutics' obesity drug meets main goal in mid-stage study

Jun 3, 2024

June 3 (Reuters) - Structure Therapeutics ( GPCR ) said on Monday its obesity drug candidate met the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath) ...

Market Chatter: Blackstone Considering Sale of Alinamin Pharmaceutical

Jun 3, 2024

07:32 AM EDT, 06/03/2024 (MT Newswires) -- Blackstone (BX) is exploring the sale of Alinamin Pharmaceutical Co., a Japanese consumer healthcare firm previously owned by Takeda Pharmaceutical Co. for around 300 billion yen ($1.9 billion), Bloomberg reported on Monday, citing people familiar with the situation. Interest in Alinamin has been expressed by investment firms such as CVC Capital Partners Plc,...